RT Journal
A1 Dardick KR, Dawood RM
T1 THe availability of proguanil for overseas travelers
JF JAMA
JO JAMA
YR 1989
FD January 13
VO 261
IS 2
SP 247
OP 247
DO 10.1001/jama.1989.03420020099028
UL http://dx.doi.org/10.1001/jama.1989.03420020099028
AB To the Editor.— 
    The continuing spread of chloroquine-resistant malaria, combined with unacceptable toxicity of drugs such as Fansidar and amodiaquine for routine use, has restricted the choice of antimalarial regimens that can now be recommended. Many authorities, including the Centers for Disease Control Malaria Branch,1 now include proguanil (Paludrine, ICI Pharmaceuticals, United Kingdom) among the drugs that may be used for antimalarial prophylaxis. Proguanil is not available in the United States and many physicians are not familiar with its use or how to obtain it.Current Centers for Disease Control recommendations suggest the use of proguanil in certain limited settings. In particular, it may be used by those who will be spending longer than three weeks in rural areas of east Africa (especially Kenya and Tanzania2,3), where much of the falciparum malaria is now resistant to chloroquine. Data do not support its use in other malarious areas such